RxDoctor Payments Data

Timothy Roth, DO

Family Medicine · Clovis, CANPI 1144213604

Payments from drug & device makers

$9,535in general payments, 2019–2025

Across 521 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amarin Pharma, Inc.$1K
  • Amgen$752
  • Supernus Pharmaceuticals, Inc.$601
  • Corcept Therapeutics$534
  • Lilly USA, LLC$492
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$9,45399%
  • Education$821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,535 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$184,541
Medicare patients
139
Services billed
19,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide91$107,489
VascepaIcosapent Ethyl86$80,376
JardianceEmpagliflozin33$51,543
OzempicSemaglutide32$44,992
Repatha SureclickEvolocumab11$18,324
RybelsusSemaglutide11$18,203
SynthroidLevothyroxine Sodium75$8,956
Icosapent Ethyl16$6,514
Ezetimibe212$4,399
Rosuvastatin Calcium191$3,709
Testosterone13$3,187
YuvafemEstradiol16$3,004
Estradiol37$2,900
Atorvastatin Calcium125$1,437
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$1,175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$492$107,48991 claims
Novo NordiskOzempic, Rybelsus$383$63,19643 claims
Boehringer IngelheimJardiance$108$51,54333 claims
AbbVieSynthroid$1,798$8,95675 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Clovis

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →